Despite the pause imposed by US regulators last week on Johnson & Johnson's (J&J) coronavirus vaccine following concerns of blood clots, the jab beat expectations reporting $100 million in sales.

J&J tightened its profit forecast, which showed it outperformed what was previously expected.

The vaccine was paused last week by US regulators as they reviewed reports of rare but serious blood clots in those who were inoculated.

In their forecast, the company now expects an adjusted profit of $9.42-$9.57 per share, which was previously $9.40-$9.60 per share, following successful sales.

Their net earnings also rose by nearly seven percent ($6.20 billion), according to Al Arabiya.

Additionally, J&J sales rose  $22.32 billion, or 7.9 percent, compared to their forecasted sales were $21.98 billion.